Answers are grounded in this paper and cite their sources.
A multi-center study was conducted to assess the clinical effectiveness and safety of high-strength capsaicin cream 0.25% in a lidocaine-containing vehicle for treatment of painful diabetic neuropathy (PDN) and postherpetic neuralgia (PHN). Eighty-three (83) patients with PDN (n = 56) or PHN (n = 27) who were already taking oral antiepileptics or tricyclic antidepressants with incomplete pain relief were enrolled. Capsaicin cream 0.25% in a lidocaine-con-taining vehicle was applied to painful areas three times daily for 6 weeks. Pain intensity was evaluated at Weeks 1,3, and 6 using an Average Weekly Pain Score. At Week 6, improvement was also assessed with a Subject Global Evaluation (SGE), a Physician Global Evaluation (PGE), and a Functional Assessment Questionnaire. Following 1,3, and 6 weeks of treatment, pain was reduced by 21%, 40%, and 50%, respectively, in patients with PDN, and by 24%, 39%, and 51%, respectively, in patients with PHN. On the SGE, 90% of patients with PDN were rated as Improved, with 58% rated as Much or Very Much Improved; 94% of patients with PHN were rated as Improved, with 56% rated as Much or Very Much Improved. On the PGE, 89% of patients with PDN were rated as Improved, with 63% rated as Much or Very Much Improved; 88% of patients with PHN were rated as Improved, with 63% rated as Much or Very Much Improved. Transient stinging/burning sensations at the application sites were the most commonly reported adverse events, while no serious adverse events related to study drug were observed. Capsaicin cream 0.25% in a lidocaine-containing vehicle was shown to be a safe, effective, and well tolerated adjunctive treatment for PDN and PHN in patients experiencing incomplete pain relief despite taking oral antiepileptics or tricyclic antidepressants.
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: